Ionis reports third quarter financial results

Advanced key priorities: initiated manufacturing infrastructure project to support growth

Increased 2022 cash and investments guidance

CARLSBAD, Calif.,Nov. 9, 2022/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq:IONS) (the "Company") today reported financial results for the third quarter of 2022. Financial results are summarized below:

Three months ended

September 30,

Nine months ended

September 30,

2022

2021

2022

2021

(amounts in millions)

Total revenue

$160

$133

$435

$370

Operating expenses

$219

$219

$637

$621

Operating expenses on a non-GAAP basis

$195

$185

$562

$499

Net loss

($47)

($82)

($217)

($253)

Net loss on a non-GAAP basis

($23)

($48)

($142)

($131)

• Revenue increased 20% for the third quarter of 2022 and 18% on a year-to-date basis compared to the same periods last year driven by significant partner payments earned across multiple programs

• Non-GAAP operating expenses increased 5% for the third quarter of 2022 and 13% on a year-to-date basis compared to the same periods last year driven by advancing Phase 3 pipeline

• Entered into a long-term lease inOctober 2022to construct a new manufacturing facility supporting continued growth

• Entered into a sale-leaseback transaction inOctober 2022for several real estate assets, generating net proceeds of$240 millionplus full funding to expand R&D campus

• Reaffirmed 2022 P&L guidance; increased cash and investments guidance to approximately$2.0 billion

• Presented positive data from the Phase 3 NEURO-TTRansform study of eplontersen in patients with polyneuropathy caused by hereditary TTR amyloidosis; on track to file U.S. New Drug Application this year

• Expanded enrollment in the Phase 3 CARDIO-TTRansform study of eplontersen in patients with ATTR cardiomyopathy; data still expected first half of 2025

• NDA for tofersen was accepted and granted priority review by the FDA; Prescription Drug User Fee Act date ofApril 25, 2023

• Initiated CORE2, a confirmatory Phase 3 study of olezarsen in patients with severe hypertriglyceridemia (SHTG)

• Initiated ESSENCE, a supporting Phase 3 study of olezarsen in patients with SHTG or hypertriglyceridemia and cardiovascular disease

• GSK presented positive end of study data from the Phase2bB-Clear study of bepirovirsen demonstrating potential for functional cures in patients with chronic hepatitis B; GSK plans to advance bepirovirsen into Phase 3 development in the first half of 2023

• Presented positive data from the Phase 2 study of IONIS-FB-LRxin patients with immunoglobulin A nephropathy; Roche plans to advance IONIS-FB-LRxinto Phase 3 development in the first half of 2023

• Bayer presented positive data from the Phase2bstudy of fesomersen in patients with end-stage renal disease; Ionis regained rights to fesomersen from Bayer and is assessing next steps

• Roche presented the Phase 2 GENERATION HD2 study design of tominersen in Huntington's disease patients; Roche plans to begin enrollment in early 2023

• Reported ION449 (AZD8233) targeting PCSK9 met the primary endpoint in Phase2bSOLANOstudy in patients with hypercholesterolemia; based on pre-specified efficacy criteria, AstraZeneca is not advancing ION449

"We have made significant progress on our key priorities this year, building our commercial pipeline, delivering an abundance of new medicines to the market and expanding and diversifying our technology. We delivered positive data from eight key programs, positioning us to potentially add two new marketed medicines to our portfolio and expand our rich Phase 3 pipeline to eight medicines next year. Additionally, we have recently begun work on a manufacturing facility to support our pipeline growth," said Brett P. Monia, Ph.D., chief executive officer of Ionis. "As we advance our near-term opportunities, including filing the NDA this year for eplontersen, and expanding our rich late-stage pipeline, we are well positioned to drive increasing value for all stakeholders."

Ionis' revenue was comprised of the following:

Three months ended

Nine months ended

September 30,

September 30,

2022

2021

2022

2021

Revenue:

(amounts in millions)

Commercial revenue:

SPINRAZA royalties

$62

$67

$175

$199

TEGSEDI and WAYLIVRA revenue, net

6

15

23

47

Licensing and royalty revenue

5

3

25

9

Total commercial revenue

73

85

223

255

Research and development revenue:

Amortization from upfront payments

18

17

54

57

Milestone payments

15

28

60

48

License fees

35

-

37

-

Other services

1

3

6

10

Collaborative agreement revenue

69

48

157

115

Eplontersen joint development revenue

18

-

55

-

Total research anddevelopment revenue

87

48

212

115

Total revenue

$160

$133

$435

$370

Total revenue for the three and nine months endedSeptember 30, 2022increased 20 percent and 18 percent compared to the same periods last year, respectively. The increase was driven by significant payments Ionis earned across multiple partnered programs. R&D revenue for the nine months endedSeptember 30, 2022included$85 millionfrom Biogen for advancing several neurology disease programs,$63 millionfrom Roche for licensing and advancing IONIS-FB-LRxand$55 millionfrom AstraZeneca for its share of the global Phase 3 development costs for eplontersen.

Commercial revenue for the three and nine months endedSeptember 30, 2022decreased 15 percent and 13 percent compared to the same periods last year, respectively. SPINRAZA royalties for the three and nine months endedSeptember 30, 2022decreased 7 percent and 12 percent compared to the same periods last year, respectively. In the U.S., SPINRAZA sales were flat in the first nine months of 2022 compared to the same period last year. Outside of the U.S. SPINRAZA royalties were lower due to lower SPINRAZA product sales primarily due to decreased pricing, foreign currency exchange and competition. TEGSEDI and WAYLIVRA revenue was also lower due to the shift to distribution fees in 2021.

Ionis' non-GAAP operating expenses increased for the three and nine months endedSeptember 30, 2022compared to the same periods in 2021, in line with expectations. For both periods, higher R&D expenses were driven by the expanded number of Phase 3 studies the Company is conducting, which doubled from three to six studies in 2021. SG&A expenses increased for the three months endedSeptember 30, 2022compared to the same period last year driven by Ionis' go-to-market activities for eplontersen, donidalorsen and olezarsen. SG&A expenses were lower for the nine months endedSeptember 30, 2022compared to the same period last year largely due to the substantial savings the Company achieved from integrating Akcea and restructuring its commercial operations in 2021.

As ofSeptember 30, 2022, Ionis had cash, cash equivalents and short-term investments of$2.0 billion, compared with$2.1 billionatDecember 31, 2021. Ionis' debt obligations and working capital did not change significantly fromDecember 31, 2021toSeptember 30, 2022.

InOctober 2022, Ionis entered into a sale and leaseback transaction for several of its real estate assets. Under the agreement, Ionis will receive net proceeds of approximately$240 millionplus full funding to expand the Company's R&D campus. The net proceeds reflect the Company's extinguishment of its mortgage debt for the related properties. Ionis' fourth quarter financial results will reflect the impact this transaction.

The Company reaffirmed its full year 2022 guidance for total revenue, operating expenses and net loss, on a non-GAAP basis. The Company's 2022 operating expense guidance, compared to the prior year, includes increasing R&D expenses between 25% and 30% and consistent SG&A expenses. Ionis expects to recognize a substantial gain on the sale of its real estate assets in the fourth quarter. The gain will not impact the Company's non-GAAP results since the sale was non-recurring and not part of the Company's normal business operations.

The Company increased its full year 2022 cash and investments guidance to approximately$2.0 billionfrom the previous guidance of$1.7 billion.

Full Year 2022 Guidance

Current

As of 3Q22

Previous

As of 2Q22

Revenue

>$575 million

>$575 million

Operating expenses on a non-GAAP basis

$825-$850 million

$825-$850 million

Net loss on a non-GAAP basis

<$275 million

<$275 million

Cash, cash equivalents and short-term investments

~$2.0 billion

~$1.7 billion

"Our strong year-to-date results, including year-over-year revenue growth of nearly 20 percent, keep us on track to meet our 2022 P&L guidance," said Elizabeth L. Hougen, chief financial officer of Ionis. "Additionally, we recently bolstered our balance sheet when we unlocked net proceeds of approximately$240 millionplus full funding to expand our R&D campus by capitalizing on the favorable life sciences real estate market and monetizing several of our facilities through a sale and leaseback transaction. As a result, we are increasing our 2022 cash and short-term investment guidance to approximately$2 billion."

Management will host a conference call and webcast to discuss Ionis' third quarter 2022 results at11:30 a.m. Eastern time on Wednesday, November 9, 2022. Interested parties may access the webcasthere. A webcast replay will be available for a limited time at the same address. To access the Company's third quarter 2022 earnings slides clickhere.

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.

To learn more about Ionis visitwww.ionispharma.comor follow us on Twitter @ionispharma.

This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of SPINRAZA (nusinersen), TEGSEDI (inotersen), WAYLIVRA (volanesorsen), eplontersen, olezarsen, donidalorsen, ION363, pelacarsen, tofersen, Ionis' technologies and Ionis' other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year endedDecember 31, 2021, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals®is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics®is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI®is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA®is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA®is a registered trademark of Biogen.

Three months ended,

Nine months ended

September 30,

September 30,

2022

2021

2022

2021

(unaudited)

Revenue:

Commercial revenue:

SPINRAZA royalties

$62

$67

$175

$199

TEGSEDI and WAYLIVRA revenue, net

6

15

23

47

Licensing and royalty revenue

5

3

25

9

Total commercial revenue

73

85

223

255

Research and development revenue:

Collaborative agreement revenue

69

48

157

115

Eplontersen joint development revenue

18

-

55

-

Total research and development revenue

87

48

212

115

Total revenue

160

133

435

370

Expenses:

Cost of sales

2

3

10

9

Research, development and patent

183

185

525

464

Selling, general and administrative

34

31

102

148

Total operating expenses

219

219

637

621

Loss from operations

(59)

(86)

(202)

(251)

Other expense (income)

12

2

(12)

(3)

Loss before income tax benefit (expense)

(47)

(84)

(214)

(254)

Income tax benefit (expense)

-

2

(3)

1

Net loss

($47)

($82)

($217)

($253)

Basic and diluted net loss per share

($0.33)

($0.58)

($1.53)

($1.80)

Shares used in computing basic and diluted net loss per share

142

141

142

141

Three months ended

September 30,

Nine months ended

September 30,

2022

2021

2022

2021

(unaudited)

$183

$185

$525

$464

Excluding compensation expense related to equity awards

(18)

(23)

(55)

(72)

Excluding Akcea merger and restructured commercial operation costs*

-

(2)

-

(8)

$165

$160

$470

$384

$34

$31

$102

$148

Excluding compensation expense related to equity awards

(6)

(7)

(19)

(26)

Excluding Akcea merger and restructured commercial operation costs*

-

(1)

-

(16)

$28

$23

$83

$106

$219

$219

$637

$621

Excluding compensation expense related to equity awards

(24)

(31)

(75)

(98)

Excluding Akcea merger and restructured commercial operation costs*

(3)

-

(24)

$195

$185

$562

$499

($59)

($86)

($202)

($251)

Excluding compensation expense related to equity awards

(24)

(31)

(75)

(98)

Excluding Akcea merger and restructured commercial operation costs*

-

(3)

-

(24)

($35)

($52)

($127)

($129)

($47)

($82)

($217)

($253)

Excluding compensation expense related to equity awards

(24)

(31)

(75)

(98)

Excluding Akcea merger and restructured commercial operation costs*

-

(3)

-

(24)

($23)

($48)

($142)

($131)

*In October 2020, Ionis completed a merger transaction with Akcea such that following the completion of the merger Akcea became a wholly owned subsidiary of Ionis. Additionally, in December 2020 and April 2021, Ionis restructured its European operations and its North American TEGSEDI operations, respectively, as a result of entering into distribution agreements with Sobi. The Company excluded the Akcea merger and restructured commercial operation costs from its non-GAAP amounts for the applicable periods.

As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. In 2021 all non-GAAP amounts also excluded expenses related to the Akcea merger and restructured commercial operations. Expenses related to the Akcea merger and restructured commercial operations included: severance costs, retention costs and other costs related to commercial operations. Ionis has regularly reported non-GAAP measures for operating results as non-GAAP results. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.

Phase 3 Development:Ionis leads and conducts

Eplontersen JointDevelopmentRevenue

(R&D Revenue)

$55M

55% of Total Phase 3development expenses,includinginternal+external costs &CMC costs, net of Ionis'share of AstraZeneca'sPhase 3 developmentexpenses

DevelopmentExpenses

(R&D Expenses)

$107M

100% of Ionis' Phase 3development expenses

Ionis' financial results for the nine months endedSeptember 30, 2022reflected the cost-sharing provisions related to its collaboration with AstraZeneca to develop and commercialize eplontersen for the treatment of ATTR. Under the terms of the collaboration agreement, AstraZeneca is paying 55 percent of the costs associated with the ongoing global Phase 3 development program. Because Ionis is leading and conducting the Phase 3 development program, Ionis is recognizing the 55 percent of cost-share funding AstraZeneca is responsible for, net of Ionis' share of AstraZeneca's development expenses, as R&D revenue in the same period Ionis incurs the related development expenses. For the nine months endedSeptember 30, 2022Ionis earned$55 millionin joint development revenue under this collaboration.

Because AstraZeneca is responsible for the majority of the medical affairs and commercial costs in the U.S. and all costs associated with bringing eplontersen to market outside the U.S., Ionis is recognizing cost-share funding it receives from AstraZeneca related to these activities as a reduction of its medical affairs (R&D expenses) and commercialization expenses (SG&A expenses). For the nine months endedSeptember 30, 2022Ionis recognized$1.4 millionand$1.5 millionof medical affairs expenses and commercialization expenses for eplontersen, respectively, net of cost-share funding from AstraZeneca. Ionis expects its medical affairs and commercialization expenses to increase as this collaboration progresses.

September 30,

December 31,

2022

2021

(unaudited)

Assets:

Cash, cash equivalents and short-term investments

$1,982

$2,115

Contracts receivable

7

62

Other current assets

164

168

Property, plant and equipment, net

181

178

Other assets

88

89

Total assets

$2,422

$2,612

Liabilities and stockholders' equity:

Other current liabilities

$184

$143

Current portion of deferred contract revenue

100

98

0% convertible senior notes, net

621

619

0.125% convertible senior notes, net

544

542

Long-term obligations, less current portion

84

86

Long-term deferred contract revenue

295

352

Total stockholders' equity

594

772

Total liabilities and stockholders' equity

$2,422

$2,612

Tofersen

NDA acceptance

SOD1-ALS

✓

Eplontersen (TTR)

NDA filing

ATTRv polyneuropathy

•

Eplontersen (TTR)

Phase 3

ATTRv polyneuropathy

✓

Tofersen

Phase 3 OLE

SOD1-ALS

✓

Tominersen (HTT)

Phase 3 post hoc

Huntington's disease

✓

ION449 (PCSK9)

Phase 2b(ETESIAN)

Cardiovascular disease

✓

Bepirovirsen (HBV)

Phase 2b

Hepatitis B virus infection

✓

Donidalorsen (PKK)

Phase 2

HAE

✓

IONIS-C9Rx(BIIB078)

Phase 1/2

C9-ALS

✓

Fesomersen (FXI)

Phase 2b

Thrombosis

✓

IONIS-FB-LRx

Phase 2

Immunoglobulin A nephropathy

✓

ION449 (PCSK9)

Phase 2b(SOLANO)

Cardiovascular disease

✓

Donidalorsen (PKK)

Phase 2 OLE

HAE

•

IONIS-AGT-LRx

Phase 2b

Treatment-resistant hypertension

­•

Cimdelirsen (GHR)

Phase 2 (monotherapy)

Acromegaly

•

Sapablursen (TMPRSS6)

2

Polycythemia vera

✓

ION904 (AGT)

2

Uncontrolled hypertension

✓

IONIS-MAPTRx(BIIB080)

2

Alzheimer's disease

•

ION717 (PRNP)

1/2

Prion disease

•

SMA

Advance follow-on program

✓

Muscle LICA

Advance into preclinical development (IND-supporting)

✓

MsPA Backbone

Advance into preclinical development (IND-supporting)

✓

✓= achieved      • = planned

(1)    Timing expectations based on current assumptions and subject to change.